Morgan Stanley trims Pliant Therapeutics stake to 0.9%

Morgan Stanley filed an amended Schedule 13G/A reporting its beneficial ownership in Pliant Therapeutics, Inc. common stock.

Rhea-AI Filing Summary

Morgan Stanley filed an amended Schedule 13G/A reporting its beneficial ownership in Pliant Therapeutics, Inc. common stock. The firm reports beneficial ownership of 545,228 shares, with shared voting power over 544,224 shares and shared dispositive power over 545,228 shares. This position represents 0.9% of Pliant’s common stock as of the event date of 12/31/2025.

Morgan Stanley notes that, as of this date, it has ceased to be the beneficial owner of more than five percent of this class of securities. The filing also states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Morgan Stanley (MS) report in this Schedule 13G/A for Pliant Therapeutics?

Morgan Stanley reported beneficial ownership of 545,228 shares of Pliant Therapeutics, Inc. common stock, representing 0.9% of the class as of 12/31/2025.

Has Morgan Stanley’s ownership in Pliant Therapeutics changed in a significant way?

Yes. Morgan Stanley stated that, as of the date of this filing, it has ceased to be the beneficial owner of more than five percent of Pliant Therapeutics’ common stock.

How much voting and dispositive power does Morgan Stanley report over Pliant Therapeutics shares?

Morgan Stanley reports shared voting power over 544,224 shares and shared dispositive power over 545,228 shares, with no sole voting or dispositive power.

Why does Morgan Stanley say it holds Pliant Therapeutics shares?

Morgan Stanley certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.

Who signed the Schedule 13G/A filing on behalf of Morgan Stanley?

The filing was signed by Christopher O'Hara as an Authorized Signatory of Morgan Stanley on 01/08/2026.

What class of Pliant Therapeutics securities is covered in Morgan Stanley’s filing?

The filing covers Common Stock of Pliant Therapeutics, Inc., identified by CUSIP number 729139105.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 04:03 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

PLIANT THERAPEUTICS, INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

729139105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 729139105

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 544,224.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 545,228.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

545,228.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PLIANT THERAPEUTICS, INC
(b)	Address of issuer's principal executive offices: 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
Item 2.
(a)	Name of person filing: Morgan Stanley
(b)	Address or principal business office or, if none, residence: 1585 Broadway, New York, NY 10036
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 729139105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 0.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	01/08/2026